Tina E. Wood

Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad et al. · Journal of Clinical Oncology · 2011 · 1K citations · Full text

Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

Andres Forero‐Torres, Jatin J. Shah, Tina E. Wood et al. · Cancer Biotherapy and Radiopharmaceuticals · 2010 · 141 citations · Full text

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

E. Gabriela Chiorean, Daniel D. Von Hoff, Michele Reni et al. · Annals of Oncology · 2016 · 100 citations · Full text

Peripheral neuropathy associated with capecitabine

Muhammad Wasif Saif, Tina E. Wood, Philip J. McGee et al. · Anti-Cancer Drugs · 2004 · 50 citations

Neuropathic Pain, Pharmacotherapy, Peripheral Nerves +20

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

MN Saleh, Ivor Percent, Tina E. Wood et al. · Journal of Clinical Oncology · 2008 · 26 citations · Full text

Immunology, Cell Death, Cs- 1008 +18